Halozyme Expands argenx Collaboration to Eight Targets with ENHANZE® Technology
Event summary
- Halozyme expands its collaboration with argenx to include two additional exclusive targets for ENHANZE® technology, increasing the total from six to eight.
- The agreement builds on the successful development of VYVGART Hytrulo, a subcutaneous formulation for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP).
- Halozyme is eligible to receive milestone payments and royalties on net sales of products using ENHANZE® technology.
- ENHANZE® has been licensed to over 15 leading pharmaceutical and biotechnology companies, including Roche, Takeda, and Pfizer.
- Halozyme's drug delivery technology portfolio includes Hypercon™ and Aerocon™, complementing ENHANZE® by enabling the creation and delivery of highly concentrated biologics.
The big picture
Halozyme's expansion of its collaboration with argenx underscores the growing industry trend towards patient-centric drug delivery solutions. The deal highlights the strategic value of ENHANZE® technology in reducing treatment burden and improving convenience, particularly in the immunology space. With over 15 partnerships already in place, Halozyme is positioning itself as a key player in the subcutaneous drug delivery market, potentially influencing future collaborations and market dynamics.
What we're watching
- Technology Validation
- Whether the expansion to eight targets will further validate ENHANZE® as the leading platform for rapid, large-volume subcutaneous delivery.
- Revenue Growth
- The pace at which Halozyme can achieve milestone payments and royalties from the expanded collaboration with argenx.
- Market Penetration
- How the addition of two new exclusive targets will impact Halozyme's growing portfolio of partnered programs and long-term opportunity for ENHANZE® across therapeutic areas.